ISHLT2026: Industry Symposia - Friday

CareDx

Beyond Histology: The MERIT of Molecular Phenotyping with HeartCare

Primary Core Therapy: Heart | Primary Practice Area: Cardiology

Join CareDx for an interactive symposium featuring real-world patient case examples, including novel use of HeartCare, landmark data from SHORE, and innovative clinical scenarios.

Moderator

Jeffrey Teuteberg, MD, CareDx, Palo Alto, CA USA

Speakers

Anne van Beuningen, MD, Emory University, Atlanta, GA USA
Nir Uriel, MD, New York Presbyterian, New York, NY USA
Yas Moayedi, MD, University Health Network, Toronto, ON Canada
Snehal Patel, MD, Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY USA

Natera

dd-cfDNA Beyond Rejection: Decoding Molecular Injury in Lung Transplantation

Primary Core Therapy: Lung | Primary Practice Area: Pulmonology

This symposium highlights how dd-cfDNA not only rules out rejection with high confidence, but also detects broader allograft injury. Experts will discuss emerging data on EMI, which is strongly linked to poor outcomes, including increased risk of CLAD.

Moderator

Nirmal Sharma, MD, Baylor St. Luke's Medical Center, Houston, TX USA

Program

Patient Case of Extreme Molecular Injury (EMI)

Holly Keyt, MD, UT Health San Antonio, San Antonio, TX USA
Present case demographics, pre-transplant and acute post-txp history

The Expanding Role of dd-cfDNA in Lung Transplantation: Clinical Implications of Molecular Injury

Fatima Anjum, MD, MHA, Temple Health, Philadelphia, PA USA
Didactic review of published literature on EMI, Temple data

Mt. Sinai Protocol To Treat Elevated dd-cfDNA Even in the Absence of AR or Infection

Jason Li, MD, Mount Sinai, New York, NY USA
Review of Mt. Sinai protocol for treatment of dd-cfDNA elevated in the absence of AR or infection, case studies

Traferox

Reaching 200 Transplants per Year: How Improved Preservation Can Drive Outcomes & Volume in Lung & Heart Programs

Primary Core Therapy: Lung | Primary Practice Area: Cardiothoracic Surgery

10°C organ preservation is redefining what is possible in heart and lung transplantation by improving organ protection, simplifying logistics, and offering a more scalable approach to improved preservation. This symposium will explore the underlying science and mechanisms supporting 10°C preservation, review the growing body of clinical evidence in heart and lung preservation, and consider how improved preservation strategies can unlock higher transplant volumes – creating a path to 200 heart and 200 lung transplants per year.

Moderator

Shaf Keshavjee, MD, MSc, FRCSC, FACS, University Health Network, Toronto, ON Canada
Ashish Shah, MD, FACS, Vanderbilt University Medical Center, Nashville, TN USA

Program

Introduction

Shaf Keshavjee, MD, MSc, FRCSC, FACS, University Health Network, Toronto, ON Canada
Ashish Shah, MD, FACS, Vanderbilt University Medical Center, Nashville, TN USA

10°C Preservation: The Science and Mechanisms Behind Improved Preservation

Marcelo Cypel, MD, MSc, FACS, FRCSC, University Health Network, Toronto, ON Canada

10°C Lung Preservation: Clinical Trials and Experience

Konrad Hoetzenecker, MD, PhD, MIB, Vanderbilt University Medical Center, Nashville, TN USA

Improved Outcomes & Logistics: Experience with >140 Hearts Preserved at 10°C

Aaron Williams, MD, Vanderbilt University Medical Center, Nashville, USA

Closing Remarks: Reaching 200 Lung & 200 Heart Transplants a Year

Shaf Keshavjee, MD, MSc, FRCSC, FACS, University Health Network, Toronto, ON Canada
Ashish Shah, MD, FACS, Vanderbilt University Medical Center, Nashville, TN USA

Q&A

Therakos (UK) Ltd

Modern Transplant Care: Early Intervention Approaches for Allograft Protection

Primary Core Therapy: Lung | Primary Practice Area: Research & Immunology

Explore how advances in immunobiology, clinical research, and real‑world data are reshaping early intervention strategies for allograft injury and rejection in cardiothoracic transplantation, with the aim of improving long‑term graft function and patient outcomes.

Moderator

Stephen Juvet, MD, PhD, University Health Network, Toronto, ON Canada

Program

Welcome and Introduction

Stephen Juvet, MD, PhD, University Health Network, Toronto, ON Canada

From Injury to Immune Reset: Translational Insights Into Allograft Immunobiology in 2026

Andrew Gelman, PhD, Washington University School of Medicine, St. Louis, MO USA

Heart Allograft Protection in 2026: Early Intervention to Improve Long‑Term Outcomes

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

Lung Allograft Protection in 2026: Early Intervention to Improve Long‑Term Outcomes

Andrew Fisher, FRCP, PhD. Newcastle University, Newcastle upon Tyne, United Kingdom